Published December 20, 2024
| Version v1
Journal article
Open
Optimal Endocrine Therapy for Premenopausal Women with Breast Cancer
Authors/Creators
-
1.
American Association of Gynecologic Laparoscopists
Description
Hormone receptor-positive breast cancer treatment involves suppressing estrogen levels, particularly in postmenopausal women. Aromatase inhibitors (AIs) and selective estrogen receptor degraders (SERDs) are effective in postmenopausal women, but their use in premenopausal women requires additional strategies to suppress ovarian estrogen production. Ovarian function suppression (OFS) combined with AIs is a cornerstone of adjuvant endocrine therapy for high-risk premenopausal patients, significantly improving invasive disease-free survival and overall survival. A personalized and multidisciplinary approach is essential to address treatment-related side effects and ensure comprehensive care for premenopausal women with breast cancer.
Files
Optimal Endocrine Therapy for Premenopausal Women with Breast Cancer – Dr. Makedonskaia & Expert Synergy Group, Inc_.pdf
Additional details
Identifiers
Software
- Repository URL
- https://oncolog.org/2024/12/20/optimal-endocrine-therapy-for-premenopausal-women-with-breast-cancer/
- Programming language
- CSS , Python , HTML , Java , JavaScript
- Development Status
- Active
References
- Makedonskaia, S. (2024). Aromatase inhibitors in breast cancer. https://doi.org/10.5281/ZENODO.14537065